UK approves Pfizer/BioNTech vaccine for use...

Dhaka, Friday   22 January 2021

UK approves Pfizer/BioNTech vaccine for use

 International Desk

 Published: 02:24 PM, 2 December 2020   Updated: 03:26 PM, 2 December 2020



The United Kingdom is the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine.

“The vaccine, which is 95 percent resistant to coronavirus, is now safe for use,” says MHRA, UK’s regulatory body.

It is learned that the vaccine will be administered to the most at-risk people in the next few days.

The UK has already demanded 40 million vaccines, which could be used to vaccinate 20 million people. Two doses will be given per person. 10 million vaccines will be available very soon.

The process of inventing the vaccine was completed in just 10 months, a process that took more than a decade to complete.

Experts say that even after the vaccine is introduced, people still need to be vigilant and strictly follow hygiene precautions to prevent the outbreak of coronavirus – which means people still have to maintain social distance and use masks. At the same time, the symptoms should be examined and they should be isolated.

So far, the effectiveness of Pfizer and BioNTech vaccines has been tested on 43,500 people in six countries and no risk has been identified.

Several vaccines are being developed around the world. Some of them have reached the final stage.

This is the first time the vaccine has been so successful.

A completely different method has been used for this vaccine so that the genetic code of the virus is injected into the body to train the human immune system.

Previous experiments have shown that the vaccine produces antibodies and another part of the body’s immune system, known as T-cells.

Two doses of this vaccine should be given every three weeks.

The vaccine has been tested in the United States, Germany, Brazil, Argentina, South Africa and Turkey. Tests have shown that seven days after the second dose, the human body is 90 percent capable of resisting the virus.